Odevixibat

Overview

Odevixibat is a potent inhibitor of the ileal bile acid transporter (IBAT), which is used in the treatment of progressive familial intrahepatic cholestasis to reduce serum bile acids. It works by decreasing bile acid reabsorption and increasing fecal excretion, thus alleviating the symptoms of cholestasis.

Patent & exclusivity (US)

Per the FDA Orange Book (4 approved US products), the latest listed US patent on Odevixibat expires 12 Nov 2041 and exclusivity 12 Jun 2030. Generic API sourcing typically opens up once these lapse.

Therapeutic areas